Pharmacokinetics of BIBR 277 in Hypertensive Patients

Inclusion criteria

• Age: >=20 years
• Sex: Either male or female
• Patient status: Either inpatient or outpatient, provided that the patient was available for hospitalisation from the day before the trial medication administration until the morning of the day after administration
• BP: Sitting systolic and diastolic blood pressures (SBP and DBP) taken the day before administration should be >= 150 mmHg and >= 90 mmHg, respectively. Patients undergoing treatment with other antihypertensives were not excluded provided the above criteria were satisfied.

Exclusion criteria

• Malignant hypertension
• Renovascular hypertension
• Severe heart failure (NYHA functional class III - IV), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset)
• Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
• Symptoms of cerebrovascular disorder
• Serious hepatic dysfunction
• Renal function disorder (serum creatinine >= 4.0 mg/dL)
• Known hypersensitivity to angiotensin II receptor antagonists
• Hyperkalaemia (potassium >= 5.5 milliequivalents per liter (mEq/L))
• Treatment with the other investigational drug within 6 months of initiation of the present study
• Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
• Previous treatment with the trial medication of the present study
• Otherwise judged ineligible by the investigator